Results of the X-PECT study: A phase III randomized double-blind placebo-controlled study of perifosine plus capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with refractory metastatic colorectal cancer (mCRC).
2012 ◽
Vol 30
(15_suppl)
◽
pp. LBA3501-LBA3501
Keyword(s):
LBA3501 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Sunday, June 3, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Sunday edition of ASCO Daily News.
2012 ◽
Vol 30
(15_suppl)
◽
pp. CRA3503-CRA3503
◽
Keyword(s):
2013 ◽
Vol 31
(15_suppl)
◽
pp. 1-1
◽
Keyword(s):
2012 ◽
Vol 30
(15_suppl)
◽
pp. CRA4502-CRA4502
◽
Keyword(s):
2013 ◽
Vol 31
(15_suppl)
◽
pp. LBA3506-LBA3506
2012 ◽
Vol 30
(15_suppl)
◽
pp. CRA9013-CRA9013
Keyword(s):
2017 ◽
Vol 16
(2)
◽
pp. 103-114.e3
◽
Keyword(s):
2012 ◽
Vol 30
(15_suppl)
◽
pp. LBA5002-LBA5002
◽
Keyword(s):
2012 ◽
Vol 30
(15_suppl)
◽
pp. LBA3500-LBA3500
Keyword(s):